A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease.

Trial Profile

A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms FS-ZONE
  • Most Recent Events

    • 07 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Sep 2012 Planned end date changed from 1 Apr 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 17 May 2011 New source identified and integrated (Oregon Health and Science University).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top